First Dallas Securities Inc. Sells 732 Shares of Amgen Inc. (NASDAQ:AMGN)

First Dallas Securities Inc. trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 9.2% in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 7,257 shares of the medical research company’s stock after selling 732 shares during the period. First Dallas Securities Inc.’s holdings in Amgen were worth $1,891,000 as of its most recent SEC filing.

Other hedge funds also recently bought and sold shares of the company. Capital Performance Advisors LLP bought a new stake in shares of Amgen in the third quarter valued at about $25,000. Legacy Investment Solutions LLC acquired a new position in Amgen in the third quarter worth about $29,000. Matrix Trust Co acquired a new position in Amgen in the third quarter worth about $36,000. Heck Capital Advisors LLC acquired a new position in Amgen in the fourth quarter worth about $36,000. Finally, Livelsberger Financial Advisory acquired a new position in Amgen in the third quarter worth about $56,000. 76.50% of the stock is currently owned by institutional investors.

Amgen Trading Up 1.2 %

Shares of NASDAQ:AMGN opened at $288.87 on Tuesday. Amgen Inc. has a 12 month low of $253.30 and a 12 month high of $346.85. The company has a quick ratio of 0.96, a current ratio of 1.32 and a debt-to-equity ratio of 7.55. The company’s fifty day simple moving average is $271.06 and its 200 day simple moving average is $304.11. The firm has a market cap of $155.28 billion, a price-to-earnings ratio of 36.99, a PEG ratio of 2.87 and a beta of 0.56.

Amgen Increases Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, February 14th will be issued a dividend of $2.38 per share. This represents a $9.52 dividend on an annualized basis and a dividend yield of 3.30%. This is a positive change from Amgen’s previous quarterly dividend of $2.25. The ex-dividend date of this dividend is Friday, February 14th. Amgen’s dividend payout ratio (DPR) is presently 115.24%.

Wall Street Analyst Weigh In

Several analysts have recently weighed in on AMGN shares. Piper Sandler Companies reaffirmed an “overweight” rating and set a $310.00 price objective on shares of Amgen in a report on Thursday, January 2nd. UBS Group dropped their price objective on shares of Amgen from $335.00 to $326.00 and set a “neutral” rating for the company in a report on Thursday, October 31st. Redburn Partners dropped their price objective on shares of Amgen from $200.00 to $195.00 in a report on Wednesday, November 27th. Barclays raised their price objective on shares of Amgen from $300.00 to $315.00 and gave the stock an “equal weight” rating in a report on Monday, October 7th. Finally, Bank of America reissued an “underperform” rating and issued a $256.00 price target on shares of Amgen in a report on Tuesday, December 10th. Two research analysts have rated the stock with a sell rating, twelve have assigned a hold rating, thirteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, Amgen currently has a consensus rating of “Hold” and an average price target of $314.00.

Amgen Profile

Amgen Inc discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout.